Exploring vimentin expression and its protein interactors across diverse cancer types via the cancer genome atlas datasets: a comprehensive analysis.

The global burden of cancer is escalating, with millions of individuals diagnosed and succumbing to the disease each year. Early detection is crucial for improving patient outcomes, yet many cancers are identified at advanced stages. Vimentin (VIM) has emerged as a promising biomarker with significant diagnostic and prognostic potential. This study investigates VIM expression and promoter methylation across various cancers using The Cancer Genome Atlas (TCGA) datasets. Additionally, we analyze protein-protein interactions and mutation frequencies using advanced bioinformatics tools. Our findings reveal that VIM is overexpressed in seven cancer types, including cholangiocarcinoma, glioblastoma multiforme, and breast invasive carcinoma. Notably, VIM expression is correlated with promoter methylation in specific cancers. Furthermore, we identify complex protein interactions involving VIM, highlighting its role in critical cellular processes such as proliferation and apoptosis. These insights emphasize Vimentin's multifaceted role in cancer, suggesting its potential as both a therapeutic target and a diagnostic marker.